Novo Nordisk ® ncluding this presentatio n a s well as the company’s statutory Annual Report 2020 and Form 20 -F, 2020, and written information released, or oral statements made, to the public in the future by or on ay’, ‘will’, ‘plan’, ‘strategy’, ‘prospect’, ‘foresee’, ‘estimate’, ‘project’, ‘anticipate’, ‘can’, ‘intend’, ‘target’ and nancial performance identify forward-looking statements. Examples of such forward-looking Novo Nordisk’s products, product research, product development, product introductions and er share, capital expenditures, dividends, capital structure, net financials and other financial es such as legal proceedings, and d-looking statements involve inherent risks and uncertainties, both general and specific. Novo ould cause actual results to differ materially from those contemplated in any forward-looking d economic conditions, including interest rate and currency exchange rate fluctuations, delay or of supplies and production, product recalls, unexpected contract breaches or terminations, f competing products, reliance on information technology, Novo Nordisk’s ability to successfully ons, changes in governmental laws and related interpretation thereof, including on reimbursement, keting, perceived or actual failure to adhere to ethical marketing practices, investments in and recruit and retain the right employees, failure to maintain a culture of compliance, and epidemics the accuracy of forw ard-looking statements in this presentation, reference is made to the overview of ise any forward-looking statement after the distribution of this presentation, whether as a result of proved in the USA
Download PDF file